Abeona Therapeutics (ABEO) and Beacon Therapeutics have announced a collaborative agreement where Beacon will evaluate Abeona's proprietary AAV204 capsid for potential gene therapies targeting specific ophthalmology indications. Beacon is granted a 12-month period to assess the viability of the AAV204 capsid for these applications.
Under the agreement, Abeona will receive an upfront payment once Beacon opts to license the AAV204 capsid. Additional compensation will be provided as certain developmental milestones are met, and tiered royalties will be applied to worldwide net sales of the licensed products utilizing AAV204. The responsibility for the development and commercialization of these licensed products will rest solely with Beacon.
